ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Omeros Corporation

Omeros Corporation (OMER)

6,95
2,76
(65,87%)
Geschlossen 15 November 10:00PM
6,90
-0,05
(-0,72%)
Nach Börsenschluss: 1:59AM

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
6,90
Gebot
6,89
Fragen
6,90
Volumen
14.225.562
4,41 Tagesbereich 7,51
1,375 52-Wochen-Bereich 6,96
Marktkapitalisierung
Handelsende
4,19
Handelsbeginn
4,42
Letzte Trade
300
@
6.9
(formt)
Letzter Handelszeitpunkt
Finanzvolumen
US$ 88.762.736
VWAP
6,2397
Durchschnittliches Volumen (3 Mio.)
234.155
Ausgegebene Aktien
57.946.859
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-3,42
Gewinn pro Aktie (EPS)
-2,03
Erlöse
-
Nettogewinn
-117,81M

Über Omeros Corporation

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injec... Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Tumwater, Washington, USA
Gegründet
-
Omeros Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OMER. The last closing price for Omeros was US$4,19. Over the last year, Omeros shares have traded in a share price range of US$ 1,375 to US$ 6,96.

Omeros currently has 57.946.859 shares in issue. The market capitalisation of Omeros is US$242,80 million. Omeros has a price to earnings ratio (PE ratio) of -3.42.

Option-Flow Omeros (OMER)

Gesamtfluss

Bullisch

Nettoprämie

66k

Calls / Puts

300,00%

Käuf. / Verkä.

100,00%

OTM / ITM

0,00%

Sweeps

0,00%

OMER Neueste Nachrichten

Omeros Corporation Reports Third Quarter 2024 Financial Results

– Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30...

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market...

FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

-- Phase 3 Studies on the Horizon in both PNH and C3G -- Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug...

Omeros Corporation Reports Second Quarter 2024 Financial Results

– Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and...

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market closes...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
12.3752.31788079474.536.964.1753177754.30819482CS
42.7867.47572815534.126.964.0052383164.27127186CS
122.6461.97183098594.266.963.542341554.03774696CS
263.181.57894736843.86.963.00013180514.15769077CS
525.46379.1666666671.446.961.3754445573.62214189CS
156-1.31-15.95615103538.218.60.926842044.27054672CS
260-6.99-50.323974082113.8925.490.927359518.55840908CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
MTEMMolecular Templates Inc
US$ 0,60
(86,28%)
331,49M
QUBTQuantum Computing Inc
US$ 4,43
(66,54%)
232,55M
OMEROmeros Corporation
US$ 6,96
(66,11%)
14,23M
ADGMAdagio Medical Holdings Inc
US$ 3,71
(57,87%)
2,66M
VVPRVivoPower International PLC
US$ 1,18
(50,47%)
5,92M
SOWGSow Good Inc
US$ 4,23
(-56,88%)
2,88M
WCTWellchange Holdings Company Limited
US$ 4,08
(-48,35%)
1,27M
NVCTNuvectis Pharma Inc
US$ 5,73
(-46,30%)
1,63M
KXINKaixin Holdings
US$ 2,525
(-39,59%)
4,47M
TRNRInteractive Strength Inc
US$ 3,59
(-38,42%)
1,23M
ELABElevai Labs Inc
US$ 0,024658
(-0,17%)
1,79B
XTIAXTI Aerospace Inc
US$ 0,0565
(-1,22%)
363,98M
MTEMMolecular Templates Inc
US$ 0,60
(86,28%)
331,48M
SVMHSRIVARU Holding Ltd
US$ 0,0268
(10,74%)
245,93M
QUBTQuantum Computing Inc
US$ 4,43
(66,54%)
228,27M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht